- Email: [email protected]
PCSK9 genetic variant R46L in a Spanish population with moderate-high cardiovascular risk
Abstracts / Atherosclerosis 241 (2015) e72ee148
EAS-0417. LDL-C TARGET ATTAINMENT AMONG TREATED ACS PATIENTS IN HONG KONG AND TAIWAN: THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS) II ACS RESULTS B.P. Yan 1, F.T. Chiang 2, A. Gitt 3, M. Horack 4, V. Ashton 5, P. Brudi 6, H.P. Balaji 7, B. Ambegaonkar 5, *. 1 Department of Medicine and Therapeutics Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong, China; 2 Department of Internal Medicine and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei City, Taiwan; 3 Acting Director, Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 4 Department of Biometry, Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 5 Global Health Outcomes, Merck & Co. Inc., Whitehouse Station, USA; 6 Medical Affairs, Merck & Co. Inc., Whitehouse Station, USA; 7 Medical Affairs, MSD International GmbH, Singapore, Singapore
* Corresponding author. Aim: Patients presenting with acute coronary syndrome (ACS) remain at very high risk of future cardiovascular events. Providing optimal therapy for effective control of risk factors including dyslipidemia, hypertension and diabetes is critical to reduce future complications. We aim to identify prevalence of lipid abnormalities and therapeutic gaps among ACS patients receiving lipid lowering therapy (LLT) in Hong Kong and Taiwan. Methods: DYSIS II is a multinational, observational cross-sectional study conducted in 18 hospitals in Hong Kong (6 centers) and Taiwan (12 centers). Consecutive adult patients hospitalized for ACS event with full lipid profiles available within 24 hours of admission, on LLT 3 months or not treated at all, not participating in randomized clinical trials involving any medication, and alive at discharge were eligible. Patient characteristics, risk factors, treatment patterns, and laboratory values were collected. Low density lipoprotein cholesterol (LDL-C) target attainment was assessed based on 2011 ESC/EAS guidelines. Results: Among 270 ACS patients (76.3% male, mean age 64.4 years), 65.2% had hypertension, 50.6% hyperlipidemia, 44.7% metabolic syndrome, 39.2% type 2 diabetes, and 32.2% history of coronary heart disease. 125 (46.3%) patients were on LLT, among them only 28.8% reaching <70mg/dl LDL-C target (mean LDL-C 89.6±35.0mg/dl). Mean atorvastatin-equivalent dose was 14±12mg/day. Among treated patients, 6.4% received combination therapy with 4% receiving ezetimibe plus statin. Conclusion: Over 70% of LLT treated ACS patients in Hong Kong and Taiwan did not attain LDL-C target. Additional effective lipid lowering strategies for LDL-C target attainment are needed among these very high risk patients.
EAS-0420. PCSK9 GENETIC VARIANT R46L IN A SPANISH POPULATION WITH MODERATE-HIGH CARDIOVASCULAR RISK D. Rey-Zamora 1, R. Fabregate-Fuente 1, M. Fabregate-Fuente 1, S. TelloBlasco 1, D. Barrio-Carreras 1, A. Rodriguez-Guerrero 1, *, A. ReyesValdivia 2, A. Palomino-Antolin 1, I. Clemente-Vargas 1, E. Olariagarida 1, C. Díaz-Dominguez 1, J. Saban-Ruiz 1. 1 Endothelium and Me Cardiometabolic Medicine Unit, Ramon y Cajal Hospital, Madrid, Spain; 2 Vascular Surgery Service, Ramon y Cajal Hospital, Madrid, Spain
e131
Genotype distributions were in Hardy-Weinberg equilibrium (p>0.051). All 7male patients. Two patients had coronary artery disease(CAD) and DM2 (one died from myocardial infarction with 59 years-old and the other one is 74) and the other 3 had hyperglycemia, 3 hypertension and 2 smokers. Five with LDLc. Conclusions: In Spanish population, prevalence of PCSK9-R46L was below 3%, similar to that described in caucasian people in other studies. 5/7 patients were within target-LDL without treatment versus 1/12 in non-carriers. The presence of the allele does not protect itself for the development of coronary heart disease, at least in the presence of DM (at least if DM is associated with it).
EAS-0424. PREVALENCE OF LIPID ABNORMALITIES AMONG TREATED PATIENTS WITH STABLE CHD: THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS) II SOUTH KOREA RESULTS S.H. Lee 1, *, M.H. Jeong 2, J.M. Cho 3, W.C. Kang 4, S.H. Hur 5, D.W. Jeon 6, S.H. Lee 7, J.O. Jeong 8, B.R. Cho 9, H.C. Gwon 10, K.J. Chun 11, W. Kim 12, K.R. Han 13, K.B. Seung 14, Y.H. Kim 15, A. Gitt 16, V. Ashton 17, H.P. Balaji 18, W.H. Song 19, Y.S. Jang 1. 1 Division of Cardiology Department of Internal Medicine, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, South Korea; 2 Division of Cardiology, Chonnam National University Hospital, Gwangju, South Korea; 3 Department of Cardiology, Kyung Hee University Hospital at Gangdong Kyung Hee University College of Medicine, Seoul, South Korea; 4 Division of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea; 5 Division of Cardiology, Keimyung University Dongsan Medical Center, Daegu, South Korea; 6 Division of Cardiology Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea; 7 Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea; 8 Division of Cardiology Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea; 9 Division of Cardiology Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea; 10 Division of Cardiology Department of Medicine Cardiac and Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea; 11 Division of Cardiology Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea; 12 Division of Cardiology Department of Internal Medicine, Kyung Hee University Hospital Kyung Hee University School of Medicine, Seoul, South Korea; 13 Division of Cardiology, Kangdong Sacred Heart Hospital Hallym University College of Medicine, Seoul, South Korea; 14 Division of Cardiology Cardiovascular Center, Seoul St. Mary's Hospital The Catholic University of Korea, Seoul, South Korea; 15 Asan Medical Center University of Ulsan College of Medicine, Division of Cardiology, 16 Acting Director, Stiftung Institut fur Seoul, South Korea; Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 17 Global Health Outcomes, Merck & Co. Inc., Whitehouse Station, USA; 18 Medical Affairs, MSD International GmbH, Singapore, Singapore; 19 Division of Cardiology Department of Internal Medicine, Korea University Asan Hospital Korea University College of Medicine, Ansan, Korea
* Corresponding author.
Aim: To determine the prevalence of the PCSK9-R46L allele in moderatehigh cardiovascular risk Spanish subjects without statins treatment and its association with low-LDL levels.
Aim: Coronary heart disease (CHD) patients continue to be at very high risk for future cardiovascular events. Critical gaps exist between recommended cholesterol goals for very high risk patients and the degree of lipid control observed. We aim to identify the unmet needs in lipid target achievements and prevalence of lipid abnormalities among stable CHD patients in South Korea currently being treated with lipid lowering therapy (LLT).
Method: N¼248 patients, 57.2±13.2years, 22%females, 51%chronic hyperglycemia, 61%hypertension, 17%Coronary-Disease and 20%smokers. Lipid profile was carried out including total-cholesterol(t-C), HDL-cholesterol(HDL-C) and Triglycerides(TG),by Hitachi autoanalyzer. LDL-cholesterol(LDL-C) was calculated in subjects with TG. Results: Identified 7heterozygote R46L allele carriers and no homozygous. The frequency of the R46L allele was 2.8% of 248individuals examined.
Methods: DYSIS II is a multicenter, observational cross-sectional study conducted in 16 South Korea hospitals. Eligible adult patients had a documented history of CHD (past Acute Coronary Syndrome (ACS) events >3 months before enrollment), full lipid profile available 0-12 months prior to enrollment, on LLT 3 months or not treated at all, and not participating in randomized clinical trials involving medication. Patient characteristics, risk factors, treatment patterns, and laboratory values were
* Corresponding author.
EAS-0417. LDL-C TARGET ATTAINMENT AMONG TREATED ACS PATIENTS IN HONG KONG AND TAIWAN: THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS) II ACS RESULTS B.P. Yan 1, F.T. Chiang 2, A. Gitt 3, M. Horack 4, V. Ashton 5, P. Brudi 6, H.P. Balaji 7, B. Ambegaonkar 5, *. 1 Department of Medicine and Therapeutics Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong, China; 2 Department of Internal Medicine and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei City, Taiwan; 3 Acting Director, Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 4 Department of Biometry, Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 5 Global Health Outcomes, Merck & Co. Inc., Whitehouse Station, USA; 6 Medical Affairs, Merck & Co. Inc., Whitehouse Station, USA; 7 Medical Affairs, MSD International GmbH, Singapore, Singapore
* Corresponding author. Aim: Patients presenting with acute coronary syndrome (ACS) remain at very high risk of future cardiovascular events. Providing optimal therapy for effective control of risk factors including dyslipidemia, hypertension and diabetes is critical to reduce future complications. We aim to identify prevalence of lipid abnormalities and therapeutic gaps among ACS patients receiving lipid lowering therapy (LLT) in Hong Kong and Taiwan. Methods: DYSIS II is a multinational, observational cross-sectional study conducted in 18 hospitals in Hong Kong (6 centers) and Taiwan (12 centers). Consecutive adult patients hospitalized for ACS event with full lipid profiles available within 24 hours of admission, on LLT 3 months or not treated at all, not participating in randomized clinical trials involving any medication, and alive at discharge were eligible. Patient characteristics, risk factors, treatment patterns, and laboratory values were collected. Low density lipoprotein cholesterol (LDL-C) target attainment was assessed based on 2011 ESC/EAS guidelines. Results: Among 270 ACS patients (76.3% male, mean age 64.4 years), 65.2% had hypertension, 50.6% hyperlipidemia, 44.7% metabolic syndrome, 39.2% type 2 diabetes, and 32.2% history of coronary heart disease. 125 (46.3%) patients were on LLT, among them only 28.8% reaching <70mg/dl LDL-C target (mean LDL-C 89.6±35.0mg/dl). Mean atorvastatin-equivalent dose was 14±12mg/day. Among treated patients, 6.4% received combination therapy with 4% receiving ezetimibe plus statin. Conclusion: Over 70% of LLT treated ACS patients in Hong Kong and Taiwan did not attain LDL-C target. Additional effective lipid lowering strategies for LDL-C target attainment are needed among these very high risk patients.
EAS-0420. PCSK9 GENETIC VARIANT R46L IN A SPANISH POPULATION WITH MODERATE-HIGH CARDIOVASCULAR RISK D. Rey-Zamora 1, R. Fabregate-Fuente 1, M. Fabregate-Fuente 1, S. TelloBlasco 1, D. Barrio-Carreras 1, A. Rodriguez-Guerrero 1, *, A. ReyesValdivia 2, A. Palomino-Antolin 1, I. Clemente-Vargas 1, E. Olariagarida 1, C. Díaz-Dominguez 1, J. Saban-Ruiz 1. 1 Endothelium and Me Cardiometabolic Medicine Unit, Ramon y Cajal Hospital, Madrid, Spain; 2 Vascular Surgery Service, Ramon y Cajal Hospital, Madrid, Spain
e131
Genotype distributions were in Hardy-Weinberg equilibrium (p>0.051). All 7male patients. Two patients had coronary artery disease(CAD) and DM2 (one died from myocardial infarction with 59 years-old and the other one is 74) and the other 3 had hyperglycemia, 3 hypertension and 2 smokers. Five with LDLc. Conclusions: In Spanish population, prevalence of PCSK9-R46L was below 3%, similar to that described in caucasian people in other studies. 5/7 patients were within target-LDL without treatment versus 1/12 in non-carriers. The presence of the allele does not protect itself for the development of coronary heart disease, at least in the presence of DM (at least if DM is associated with it).
EAS-0424. PREVALENCE OF LIPID ABNORMALITIES AMONG TREATED PATIENTS WITH STABLE CHD: THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS) II SOUTH KOREA RESULTS S.H. Lee 1, *, M.H. Jeong 2, J.M. Cho 3, W.C. Kang 4, S.H. Hur 5, D.W. Jeon 6, S.H. Lee 7, J.O. Jeong 8, B.R. Cho 9, H.C. Gwon 10, K.J. Chun 11, W. Kim 12, K.R. Han 13, K.B. Seung 14, Y.H. Kim 15, A. Gitt 16, V. Ashton 17, H.P. Balaji 18, W.H. Song 19, Y.S. Jang 1. 1 Division of Cardiology Department of Internal Medicine, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, South Korea; 2 Division of Cardiology, Chonnam National University Hospital, Gwangju, South Korea; 3 Department of Cardiology, Kyung Hee University Hospital at Gangdong Kyung Hee University College of Medicine, Seoul, South Korea; 4 Division of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea; 5 Division of Cardiology, Keimyung University Dongsan Medical Center, Daegu, South Korea; 6 Division of Cardiology Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea; 7 Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea; 8 Division of Cardiology Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea; 9 Division of Cardiology Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea; 10 Division of Cardiology Department of Medicine Cardiac and Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea; 11 Division of Cardiology Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea; 12 Division of Cardiology Department of Internal Medicine, Kyung Hee University Hospital Kyung Hee University School of Medicine, Seoul, South Korea; 13 Division of Cardiology, Kangdong Sacred Heart Hospital Hallym University College of Medicine, Seoul, South Korea; 14 Division of Cardiology Cardiovascular Center, Seoul St. Mary's Hospital The Catholic University of Korea, Seoul, South Korea; 15 Asan Medical Center University of Ulsan College of Medicine, Division of Cardiology, 16 Acting Director, Stiftung Institut fur Seoul, South Korea; Herzinfarktforschung, Ludwigshafen am Rhein, Germany; 17 Global Health Outcomes, Merck & Co. Inc., Whitehouse Station, USA; 18 Medical Affairs, MSD International GmbH, Singapore, Singapore; 19 Division of Cardiology Department of Internal Medicine, Korea University Asan Hospital Korea University College of Medicine, Ansan, Korea
* Corresponding author.
Aim: To determine the prevalence of the PCSK9-R46L allele in moderatehigh cardiovascular risk Spanish subjects without statins treatment and its association with low-LDL levels.
Aim: Coronary heart disease (CHD) patients continue to be at very high risk for future cardiovascular events. Critical gaps exist between recommended cholesterol goals for very high risk patients and the degree of lipid control observed. We aim to identify the unmet needs in lipid target achievements and prevalence of lipid abnormalities among stable CHD patients in South Korea currently being treated with lipid lowering therapy (LLT).
Method: N¼248 patients, 57.2±13.2years, 22%females, 51%chronic hyperglycemia, 61%hypertension, 17%Coronary-Disease and 20%smokers. Lipid profile was carried out including total-cholesterol(t-C), HDL-cholesterol(HDL-C) and Triglycerides(TG),by Hitachi autoanalyzer. LDL-cholesterol(LDL-C) was calculated in subjects with TG. Results: Identified 7heterozygote R46L allele carriers and no homozygous. The frequency of the R46L allele was 2.8% of 248individuals examined.
Methods: DYSIS II is a multicenter, observational cross-sectional study conducted in 16 South Korea hospitals. Eligible adult patients had a documented history of CHD (past Acute Coronary Syndrome (ACS) events >3 months before enrollment), full lipid profile available 0-12 months prior to enrollment, on LLT 3 months or not treated at all, and not participating in randomized clinical trials involving medication. Patient characteristics, risk factors, treatment patterns, and laboratory values were
* Corresponding author.